Comment from Lee Hasselbacher

Summary: The Reproductive Health Outcomes and Disparities (RHOADs) Research Lab at the University of Chicago supports the petition to remove the mifepristone REMS or, at minimum, prevent actions that reduce patient access. They argue that mifepristone is safe and effective, and that current and proposed regulations create significant administrative and logistical barriers that negatively impact maternal health, socioeconomic stability, and child well-being.